CAS 1231220-79-3

Fórmula: C22H27ClN6O

InChI: InChI=1S/C22H27ClN6O/c1-15-24-21(28-11-9-27(2)10-12-28)19-22(25-15)29(16-7-13-30-14-8-16)20(26-19)17-5-3-4-6-18(17)23/h3-6,16H,7-14H2,1-2H3

Clave InChI: UCMNDPDJRSEZPL-UHFFFAOYSA-N

SMILES: CC1=NC2=C(C(=N1)N3CCN(CC3)C)N=C(N2C4CCOCC4)C5=CC=CC=C5Cl

LY2828360

CAS: 1231220-79-3

LY2828360

Fórmula: C₂₂H₂₇ClN₆O

Pureza: 99.5%

Peso molecular: 426.94

Ref: 54-BUP05731

LY2828360

CAS: 1231220-79-3

Fórmula: C₂₂H₂₇ClN₆O

Pureza: 98%

Peso molecular: 426.9424

Ref: IN-DA01EONJ

LY2828360

CAS: 1231220-79-3

LY2828360: CB2 agonist, Ki=40.3 nM; biases CB2 over CB1 with EC50s of 20.1 nM and >100 μM.

Fórmula: C₂₂H₂₇ClN₆O

Pureza: 99.45% - 99.51%

Forma y color: White Solid

Peso molecular: 426.942

Ref: TM-T7316

LY2828360

CAS: 1231220-79-3

LY2828360 is a low-potency cannabinoid receptor agonist that has been shown to antagonize the effects of the endogenous cannabinoid anandamide. This compound has been studied in clinical studies for its potential use as an anti-inflammatory and analgesic agent. LY2828360 is also a CB2 receptor agonist, which has been shown to have potential uses in treating inflammatory diseases such as arthritis, inflammatory bowel disease, or pain models. LY2828360 has also shown efficacy in animal models of colorectal adenocarcinoma and other cancers.

Fórmula: C₂₂H₂₇ClN₆O

Pureza: Min. 95%

Peso molecular: 426.94 g/mol

Ref: 3D-GZB22079